Roth Capital upgraded Alcobra Ltd (NASDAQ:ADHD) to Buy in a report released today.
- Updated: February 12, 2017
Yesterday Alcobra Ltd (NASDAQ:ADHD) traded -1.67% lower at $1.18. The company’s 50-day moving average is $1.57 and its 200-day moving average is $2.87. The last stock close price is down -58.96% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the same time. 243,137 shares of the stock were exchanged, down from an average trading volume of 726,892
Roth Capital has upgraded Alcobra Ltd (NASDAQ:ADHD) to Buy in a report released on 2/09/2017.
Previously on 1/18/2017, Jefferies Group LLC reported about Alcobra Ltd (NASDAQ:ADHD) lowered the target price from $6.00 to $1.25. At the time, this indicated a possible upside of 0.25%.
See Chart Below
Alcobra Ltd has a 52 week low of $0.83 and a 52 week high of $5.75 The company’s market cap is currently $0.
In addition to Roth Capital reporting its target price, a total of 7 firms have reported on the stock. The consensus target price is $12.71 with 3 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
More About Alcobra Ltd (NASDAQ:ADHD)
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.